stockrowPalvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
Palvella Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.9 million.
- EPS
- −76.7%
- Free cash flow
- −136.4%
Quarter to June 2026, against a year earlier
Follow PVLA
Alert me
Palvella Therapeutics, Inc. (PVLA) Revenue growth
Palvella Therapeutics, Inc.'s revenue growth over the twelve months to 31 March 2024 was 146.7%, up 81.4 percentage points from fiscal 2023 (65.3%). Over the past ten years it has ranged from −45.4% (fiscal 2015) to 333.5% (fiscal 2017); the current reading is higher than 78% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2023 | 65.3% | 82.84 |
| FY2022 | −17.6% | (24.70) |
| FY2021 | 7.14% | 43.78 |
| FY2020 | −36.6% | (95.67) |
| FY2019 | 59.0% | 43.89 |
| FY2018 | 15.1% | (318.32) |
| FY2017 | 333.5% | 234.58 |
| FY2016 | 98.9% | 144.23 |
| FY2015 | −45.4% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Mar 2024 | −99.1% | (21.31) |
| Dec 2023 | −77.8% | (341.28) |
| Sep 2023 | 263.5% | (178.82) |
| Jun 2023 | 442.3% | 524.70 |
| 33 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. | 146.7% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PVLA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement